To identify systemic biomarkers associated with subclinical atherosclerosis, we quantified the plasma levels of well-established markers of gut damage (sCD14, LBP, FABP2) and systemic inflammation (CCL20/MIP-3α, MIF, CX3CL1/FKN, CCL25/TECK) in the HIV− and HIV+ groups, and in the HIV+ group in relationship with subclinical CVD. This evidence concerns the gene CCL25 and atherosclerosis.